MA45901A - Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile - Google Patents
Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrileInfo
- Publication number
- MA45901A MA45901A MA045901A MA45901A MA45901A MA 45901 A MA45901 A MA 45901A MA 045901 A MA045901 A MA 045901A MA 45901 A MA45901 A MA 45901A MA 45901 A MA45901 A MA 45901A
- Authority
- MA
- Morocco
- Prior art keywords
- azã
- acã
- thylsulfonyl
- tidin
- tonitrile
- Prior art date
Links
- -1 7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL Chemical class 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182040P | 2015-06-19 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45901A true MA45901A (fr) | 2019-06-19 |
Family
ID=56204068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045901A MA45901A (fr) | 2015-06-19 | 2016-06-16 | Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20180134713A1 (fr) |
| EP (1) | EP3310781A1 (fr) |
| JP (1) | JP2018519280A (fr) |
| KR (1) | KR20180008637A (fr) |
| CN (1) | CN107660206A (fr) |
| AR (1) | AR104918A1 (fr) |
| AU (1) | AU2016280815A1 (fr) |
| BR (1) | BR112017024613A2 (fr) |
| CA (1) | CA2984627A1 (fr) |
| CL (1) | CL2017003112A1 (fr) |
| CO (1) | CO2017013226A2 (fr) |
| CR (1) | CR20170533A (fr) |
| DO (1) | DOP2017000300A (fr) |
| EA (1) | EA201792308A1 (fr) |
| EC (1) | ECSP17083426A (fr) |
| HK (1) | HK1248699A1 (fr) |
| IL (1) | IL255386A0 (fr) |
| MA (1) | MA45901A (fr) |
| MX (1) | MX2017015837A (fr) |
| NZ (1) | NZ736999A (fr) |
| PE (1) | PE20180504A1 (fr) |
| PH (1) | PH12017502360A1 (fr) |
| SV (1) | SV2017005586A (fr) |
| TN (1) | TN2017000530A1 (fr) |
| TW (1) | TWI622591B (fr) |
| WO (1) | WO2016205487A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108341818A (zh) * | 2017-01-21 | 2018-07-31 | 南京华威医药科技开发有限公司 | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 |
| KR102485731B1 (ko) | 2017-01-23 | 2023-01-05 | 상하이 롱우드 바이오파마슈티칼스 컴퍼니 리미티드 | Jak 효소 억제제 및 이의 제조 방법과 용도 |
| CN106946917B (zh) * | 2017-03-20 | 2019-06-11 | 杭州科巢生物科技有限公司 | 一种jak抑制剂巴瑞替尼及其中间体的新合成方法 |
| CN107739328B (zh) * | 2017-11-22 | 2020-03-20 | 海化生命(厦门)科技有限公司 | 用于合成巴瑞替尼的关键中间体1的制备方法 |
| CN108129482A (zh) * | 2017-12-13 | 2018-06-08 | 江苏中邦制药有限公司 | 一种巴瑞替尼的制备方法 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| WO2020072870A1 (fr) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Formes co-cristallines du baricitinib |
| TW202033198A (zh) | 2018-10-17 | 2020-09-16 | 美商美國禮來大藥廠 | 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎 |
| US11548895B2 (en) | 2019-04-24 | 2023-01-10 | Elanco Us Inc. | Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile |
| WO2023009767A1 (fr) | 2021-07-30 | 2023-02-02 | Eli Lilly And Company | Traitement de l'eczéma des mains à l'aide de baricitinib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821374A (en) * | 1995-11-21 | 1998-10-13 | Hoffmann-La Roche Inc. | Process for the oxidation of alcohols |
| JP5275371B2 (ja) * | 2008-03-11 | 2013-08-28 | インサイト・コーポレイション | Ｊａｋ阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体 |
| KR20130094710A (ko) * | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| CN102557901B (zh) * | 2010-12-15 | 2014-06-11 | 上海医药工业研究院 | 6-氯己醛的制备方法 |
| LT2964650T (lt) * | 2013-03-06 | 2019-04-25 | Incyte Holdings Corporation | Būdai ir tarpiniai junginiai, skirti jak inhibitoriaus gamybai |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
-
2016
- 2016-06-06 AR ARP160101679A patent/AR104918A1/es unknown
- 2016-06-07 TW TW105118021A patent/TWI622591B/zh not_active IP Right Cessation
- 2016-06-16 CR CR20170533A patent/CR20170533A/es unknown
- 2016-06-16 EA EA201792308A patent/EA201792308A1/ru unknown
- 2016-06-16 CN CN201680032170.5A patent/CN107660206A/zh active Pending
- 2016-06-16 KR KR1020177036019A patent/KR20180008637A/ko active Search and Examination
- 2016-06-16 NZ NZ736999A patent/NZ736999A/en not_active IP Right Cessation
- 2016-06-16 MA MA045901A patent/MA45901A/fr unknown
- 2016-06-16 PE PE2017002470A patent/PE20180504A1/es unknown
- 2016-06-16 JP JP2017564727A patent/JP2018519280A/ja active Pending
- 2016-06-16 WO PCT/US2016/037832 patent/WO2016205487A1/fr active Application Filing
- 2016-06-16 MX MX2017015837A patent/MX2017015837A/es unknown
- 2016-06-16 TN TNP/2017/000530A patent/TN2017000530A1/en unknown
- 2016-06-16 EP EP16732192.6A patent/EP3310781A1/fr not_active Withdrawn
- 2016-06-16 CA CA2984627A patent/CA2984627A1/fr not_active Abandoned
- 2016-06-16 AU AU2016280815A patent/AU2016280815A1/en not_active Abandoned
- 2016-06-16 BR BR112017024613A patent/BR112017024613A2/pt not_active Application Discontinuation
- 2016-06-16 US US15/579,612 patent/US20180134713A1/en not_active Abandoned
-
2017
- 2017-11-01 IL IL255386A patent/IL255386A0/en unknown
- 2017-12-05 CL CL2017003112A patent/CL2017003112A1/es unknown
- 2017-12-11 SV SV2017005586A patent/SV2017005586A/es unknown
- 2017-12-18 DO DO2017000300A patent/DOP2017000300A/es unknown
- 2017-12-19 PH PH12017502360A patent/PH12017502360A1/en unknown
- 2017-12-19 EC ECIEPI201783426A patent/ECSP17083426A/es unknown
- 2017-12-21 CO CONC2017/0013226A patent/CO2017013226A2/es unknown
-
2018
- 2018-06-28 HK HK18108312.4A patent/HK1248699A1/zh unknown
- 2018-10-25 US US16/170,137 patent/US20190062337A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TN2017000530A1 (en) | 2019-04-12 |
| US20180134713A1 (en) | 2018-05-17 |
| TWI622591B (zh) | 2018-05-01 |
| CR20170533A (es) | 2018-01-25 |
| KR20180008637A (ko) | 2018-01-24 |
| AR104918A1 (es) | 2017-08-23 |
| JP2018519280A (ja) | 2018-07-19 |
| SV2017005586A (es) | 2018-04-24 |
| CA2984627A1 (fr) | 2016-12-22 |
| AU2016280815A1 (en) | 2017-11-23 |
| DOP2017000300A (es) | 2018-01-31 |
| MX2017015837A (es) | 2018-04-10 |
| US20190062337A1 (en) | 2019-02-28 |
| TW201712015A (zh) | 2017-04-01 |
| NZ736999A (en) | 2019-05-31 |
| PH12017502360A1 (en) | 2018-06-25 |
| HK1248699A1 (zh) | 2018-10-19 |
| WO2016205487A1 (fr) | 2016-12-22 |
| CN107660206A (zh) | 2018-02-02 |
| CO2017013226A2 (es) | 2018-03-28 |
| EA201792308A1 (ru) | 2018-05-31 |
| ECSP17083426A (es) | 2018-02-28 |
| EP3310781A1 (fr) | 2018-04-25 |
| BR112017024613A2 (pt) | 2018-07-31 |
| CL2017003112A1 (es) | 2018-06-01 |
| IL255386A0 (en) | 2017-12-31 |
| PE20180504A1 (es) | 2018-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45901A (fr) | Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| IL247901A0 (en) | Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile | |
| CL2014003566A1 (es) | Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson. | |
| EP3174539A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3193877A4 (fr) | Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton | |
| EP3141546A4 (fr) | Inhibiteur de la tyrosine kinase de bruton | |
| CL2016003145A1 (es) | Compuestos de [1,2,4]triazol sustituido | |
| EP3159340A4 (fr) | Nouvel inhibiteur de la tyrosine kinase de bruton | |
| EA201691327A1 (ru) | Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3299366A4 (fr) | Composés de pyrazole substitués contenant de la pyrimidine et procédé de préparation et utilisation de ceux-ci | |
| EP3426637A4 (fr) | Composés et procédés pour moduler la tyrosine kinase de bruton | |
| ZA201701131B (en) | Novel 2,5-substituted pyrimidines as pde4 inhibitors | |
| ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
| ZA201804843B (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide | |
| IL251249B (en) | Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone | |
| HK1206337A1 (en) | Crystalline forms of (s)-4-aminon-(1-(4-chlorophenyl)-3- hydroxypropyl)-1-(7h -pyrrolo[2, 3-d]pyrimidi n-4-yl) piperidine-4- carboxamide (s)-4--n-(1-(4-)-3-)-1-(7h-[23-d]-4-) -4- | |
| FR3003460B1 (fr) | Equipement pour la determination de l'œil directeur | |
| HK1203339A1 (zh) | 量度動脈網硬化指數的系統 | |
| FR3023506B1 (fr) | Applicateur de liquide, notamment de maquillage | |
| EP3412657A4 (fr) | Nouvel inhibiteur irréversible de la tyrosine kinase de bruton | |
| EP3282845A4 (fr) | Dérivés d'acide (s)-2'-vinyl abscissique | |
| IL265634A (en) | Novel 5-substituted imidazolylmethyl derivatives |